Hypersensitivity Reactions Secondary to Dupilumab in Two Patients with Moderate to Severe Atopic Dermatitis
Main Article Content
Keywords
dupilumab, biologics, atopic dermatitis, drug reaction, hypersensitivity
Abstract
References
Bieber T. Atopic Dermatitis, Annals of Dermatology. 2019;22(2):125. doi:10.5021/ad.2010.22.2.125.
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;71(2):327-349. doi.10.1016/j.jaad.2014.03.030.
Dreme AM, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Design, Development and Therapy. 2017; Volume 11:1473-1480. doi:10.2147/dddt.s113192.
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad an Targeted Therapies. Journal of Clinical Medicine. 2015;4(5):858-873. doi:10.3390/jcm4050858.
Renert-Yuval Y, Guttman-Yassky E. Systemic therapies in atopic dermatitis: The pipeline. Clinics in Dermatology. 2017;35(4):387-397. doi: 10.1016/j.clindermatol.2017.03.012.
Simpson EL, Bieber T, Guttman-Yassky E, et al, Two Phase 3 Trials of Dupilumab verses Placebo in Atopic Dermatitis. New England Journal of Medicine. 2016;375(24):2335-2348. doi:10,1056/nejmoa1610020.
Dupixent (dupilumab) [Package Insert]. Sanofi Biotechnology (Bridgewater, NJ) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Zaki S. Advere drug reaction and causality assessment scales. Lung India. 2011;28(2):152. doi:10.4103/0970-2113.80343.
Davis JD, Bansal A, Hassman D, et al. Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients with Moderate-to Severe Atopic Dermatitis Receiving Dupilumab. Clinical Pharmacology & Therapeutics. February 2018. doi:10.1002/cpt.1058.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.